Outcome of 40 adults aged from 18 to 55 years with acute lymphoblastic leukemia treated with double-delayed intensification pediatric protocol

Stéphanie Haïat; Zora Marjanovic; Simona Lapusan; Anne Vekhoff; Bernard Rio; Elise Corre; Sophie Dimicoli; Pierre Hirsch; Jean-Pierre Marie; Ollivier Legrand

doi:10.1016/j.leukres.2010.04.002

Outcome of 40 adults aged from 18 to 55 years with acute lymphoblastic leukemia treated with double-delayed intensification pediatric protocol

Leuk Res. 2011 Jan;35(1):66-72. doi: 10.1016/j.leukres.2010.04.002.

Authors

Stéphanie Haïat¹, Zora Marjanovic, Simona Lapusan, Anne Vekhoff, Bernard Rio, Elise Corre, Sophie Dimicoli, Pierre Hirsch, Jean-Pierre Marie, Ollivier Legrand

Affiliation

¹ Département d'Hématologie Hôpital Hôtel Dieu, AP-HP and Université Pierre et Marie Curie, Paris, France.

PMID: 20434771
DOI: 10.1016/j.leukres.2010.04.002

Abstract

Adolescents ALL have a better outcome when treated with pediatric protocol compared to adult protocol. We have tested the feasibility of pediatric protocol to treat 40 consecutive adults ALL. DFS and OS were 73±7%, and 72±7%, and were significantly longer in patients under 40 yo (81±9% vs 51±15%, p=0.05 [DFS] and 83±7.8% vs 45±15%, p=0.003 [OS], respectively) or cortico/chemo-sensitive (86±9% vs 36±16%, p=0.001 [DFS] and 95±4.4% vs 28±13%, p<0.0001 [OS]) than in other patients. Overall tolerance was acceptable. We have shown the feasibility of using this unmodified pediatric protocol to treat adult with ALL up to 40 years.

MeSH terms

Adolescent
Adult
Antineoplastic Combined Chemotherapy Protocols / administration & dosage
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Dose-Response Relationship, Drug
Feasibility Studies
Female
Humans
Male
Middle Aged
Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy*
Recurrence
Young Adult